AzTrials
AzTrials

COVID-19NCT06183424

TDCS Stimulation After Covid-19 Infection

A study testing Transcranial Direct Stimulation in people with COVID-19, run by Istanbul Medipol University Hospital at 1 site in Turkey (Türkiye).

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

In this study, the effects of bilateral stimulation of the dorsolateral prefrontal cortex (DLPFC) with active tDCS (transcranial direct stimulation/transcranial direct stimulation) on neurocognitive (memory and executive) functions in patients with Covid-19 infection and subjective cognitive complaints, as well as… Read more about this study

Who is it for?
Ages 18 to 50 yearsHealthy volunteers can take part
Conditions the study is for
COVID-19
What is being tested?
Transcranial Direct Stimulation
Type of treatment
Surgery or procedure
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
50 participants
Where
1 siteTurkey (Türkiye)
Study dates
1 Oct 2023to 1 Dec 2025
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 50 years
  • All sexes
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Have received a positive value from the COVID-19 RT-PCR test in the last 60 days and turned negative
  • Being between the ages of 18-50
  • 21 days have passed since the disease onset date

Who cannot join

  • Having any neurological or psychiatric disease

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Cennet Sena Parlatan, phd Cand contact

05077799164

cennet.parlatan@std.medipol.edu.tr

Turkey (Türkiye)1 site, 1 recruiting
  • Alanya Alaaddin Keykubat Üniversitesi

    Antalya

    Cennet Sena Parlatan, pHD Cand, 05077799164, cennet.parlatan@std.medipol.edu.tr

    Recruiting

Other trials in Turkey (Türkiye)

About this study

Official title: Effects of aTDCS Stimulation of the Dorsolateral Prefrontal Cortex on Cognitive Functions and the Parietal Memory Network, Default Mode Network in Patients Presenting Cognitive Symptoms After Covid-19 Infection: A Controlled Randomized Clinical Trial

In this study, the effects of bilateral stimulation of the dorsolateral prefrontal cortex (DLPFC) with active tDCS (transcranial direct stimulation/transcranial direct stimulation) on neurocognitive (memory and executive) functions in patients with Covid-19 infection and subjective cognitive complaints, as well as resting-state fMRI In the case of dfMRI, it is aimed to examine the default mode network (DMN) and parietal memory network (PMN) inter- and intra-network connectivity alterations and the hippocampal region connectivity alterations and contribute to the relevant literature.

Read the detailed description

The DMN is active when not engaged in a goal-oriented activity and at rest. Resting DNM is especially active when the mind is busy with introspective situations (Barkhof et al., 2014; Mak et al., 2017). Although the posterior parts of the DMN consisting of the posterior cingulate/precuneus and bilateral parietal cortex regions are associated with memory functions, memory functions are not unique to DMN and the parietal regions are not functionally homogeneous (Sestieri et al., 2011). At this point, a new network called the parietal memory network (PMN) was defined in a study by Gilmore (Gilmore et al., 2015). This network is a system that diverges from the posterior parts of the DMN and consists of the middle cingulate cortex, precuneus and inferior parietal lobule/angular gyrus structures and has overlapping regions with the DMN. This network appears to differ from the DMN in different types of recall memory functions. Accordingly, when recalling autobiographical information, DMN; PMN seems to be active in encoding and recall tasks related to recognition memory (McDermott et al., 2009; Chen et al., 2017; Nelson et al., 2013; Hu et al., 2016; Manenti et al., 2010; Kragel et al., 2016) . A double dissociation appears to occur between these two network systems in memory processes, and furthermore, the spacial proximity of PMN to the DMN suggests that some of the cognitive dysfunctions attributed to the DMN of these two systems are due to PMN. The fact that PMN is associated with memory encoding and recall functions even in different types of tasks (de-activity in perceiving new stimulus but being active in perceiving familiar stimulus) differentiates it from other network systems. Stimulation of the parietal region with repetitive transcranial magnetic stimulation (rTMS) resulted in improved visual recognition memory performance (Velioğlu et al., 2021).

The dorsolateral prefrontal cortex (DLPFC) is the central region associated with executive functions, and damage to this region is associated with difficulty in regulating behavioral responses, memory-retrieval, and inability to demonstrate appropriate motor behavior. Damages in this region are associated with cognitive loss in related areas (Liu et al., 2021; Brak et al., 2022). tDCS, on the other hand, stands out as a promising method for patients with Covid-19 infection and subjective cognitive complaints, and appears to act by modulating functional connectivity (Baptista, 2020; Linnhoff, 2023; Yulug B). Increased connectivity between the hippocampus and other DMN nodes such as the dorsal attention network, control, attention-attractiveness network, and sensori-motor networks was detected in fMRI with atDCS stimulation (Manenti et al., 2020; Meinzer et al., 2015). In this context, improvement in neurocognitive tests and changes in functional imaging can be detected with stimulation of the relevant regions of the cortex with tDCS in patients who have had Covid-19 infection and have subjective cognitive complaints. In patients with Covid-19 infection, stimulation of the relevant regions with tDCS resulted in improvement in cognitive functions such as working memory and cognitive control. (Baptista, 2020; Linnhoff, 2023; Yulug B,2023). At this point, DLPFC stimulation may also result in improved cognitive functions regarding encoding and recall.

From this point of view, in this study -based on the studies referenced in the text-, bilateral stimulation of the DLPFC region with anodal tDCS (atDCS) increased performance in neurocognitive abilities, especially memory and executive functions, in patients who had Covid-19 infection and had subjective cognitive complaints. The methodical mesh is shaped in the context of this template, hypothesizing that it will result in In addition, in the fMRI studies mentioned above, it is aimed to point out that tDCS stimulation increases the coherence between DMN networks and to examine the effect of tDCS stimulation on DMN network connectivity and connectivity with the hippocampal region with reference to the role of PMN in patients with Covid-19 infection and subjective cognitive complaints. From this point of view, the aim of this study is dorsolateral prefrontal cortex (DLPFC) active tDCS (transcranial direct stimulation/transcribed) in patients with covid-19 infection and subjective cognitive complaints.

Conditions
COVID-19
Being tested
Transcranial Direct Stimulation
Keywords
Covid-19, tDCS, Cognitive function
Medical subject headings
COVID-19

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Transcranial Direct StimulationProcedure or surgery

    2 mA, 20 min, 5 days

Study groups in NCT06183424
Study groupRoleWhat they receive
InterventionalActive comparatorActive tDCS stimulation will be applied over the scalp for 20 minutes at an intensity of 2 mA. Stimulation will be given for 5 days. The application will be made to the patient who has had 30 Covid and has cognition complaints in a randomized manner.
Receives: Procedure: Transcranial Direct Stimulation
ShamPlacebo comparatorFor the pseudo-stimulation to be applied to the sham group, the electrodes will be placed on the scalp in exactly the same way as the experimental group. For all stimulations, the reference electrode will be placed in the right orbital region and given once for 15 seconds, so that the participant will feel a slight tingling, but no real stimulation will be given.
Receives: Procedure: Transcranial Direct Stimulation

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Montreal cognitive assessment

    Cognition Test

    Measured: Before Treatment / 1 month after treathment

  2. Cognition Test Material

    clock drawing test, digit range test, verbal fluency test, stroop test, trail making test

    Measured: Before Treatment / 1 month after treathment

  3. NPI

    Cognition Test (Neuropsychiatric Inventory)

    Measured: Before Treatment / 1 month after treathment

  4. Öktem Verbal Memory Processes Test

    Cognition Test

    Measured: Before Treatment / 1 month after treathment

  5. Rey Complex Figure Test

    Cognition Test

    Measured: Before Treatment / 1 month after treathment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Dec 2023
  2. Study start1 Oct 2023
  3. Primary completion1 Oct 2024
  4. Study completion1 Dec 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Crossover
Masking
Single blind
Who is masked
Participant
Enrolment
50 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06183424
Sponsor's protocol ID
2023IMU_ALKU_COVID
Status last verified
Apr 2025
First submitted
25 Dec 2023
Last updated
2 May 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Transcranial Direct Stimulation in people with COVID-19, run by Istanbul Medipol University Hospital at 1 site in Turkey (Türkiye).

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 2 May 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Turkey (Türkiye). Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Cennet Sena Parlatan, phd Cand (05077799164, cennet.parlatan@std.medipol.edu.tr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Montreal cognitive assessment (time frame: Before Treatment / 1 month after treathment). The study lists 5 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 2 May 2025; AzTrials last refreshed its copy on 31 Oct 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in